BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23211224)

  • 1. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
    Paulsson AK; McMullen KP; Peiffer AM; Hinson WH; Kearns WT; Johnson AJ; Lesser GJ; Ellis TL; Tatter SB; Debinski W; Shaw EG; Chan MD
    Am J Clin Oncol; 2014 Apr; 37(2):177-81. PubMed ID: 23211224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
    McDonald MW; Shu HK; Curran WJ; Crocker IR
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):130-6. PubMed ID: 20399036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma.
    Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD
    Tumori; 2013; 99(4):480-7. PubMed ID: 24326836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
    Reddy K; Gaspar LE; Kavanagh BD; Chen C
    J Med Imaging Radiat Oncol; 2014 Dec; 58(6):714-21. PubMed ID: 24975917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
    Dhermain F
    Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
    Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
    Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
    Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
    Gebhardt BJ; Dobelbower MC; Ennis WH; Bag AK; Markert JM; Fiveash JB
    Radiat Oncol; 2014 Jun; 9():130. PubMed ID: 24906388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
    Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
    Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
    Guckenberger M; Mayer M; Buttmann M; Vince GH; Sweeney RA; Flentje M
    Strahlenther Onkol; 2011 Sep; 187(9):548-54. PubMed ID: 21858417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy.
    Press RH; Prabhu RS; Appin CL; Brat DJ; Shu HK; Hadjipanayis C; Olson JJ; Oyesiku NM; Curran WJ; Crocker I
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1004-10. PubMed ID: 24661652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
    Ali AN; Ogunleye T; Hardy CW; Shu HK; Curran WJ; Crocker IR
    Radiat Oncol; 2014 Jan; 9():20. PubMed ID: 24411020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.